Ticker >

Granules India share price

Granules India Ltd.

NSE: GRANULES BSE: 532482 SECTOR: Pharmaceuticals & Drugs  144k   1k   221

430.15
+0.10 (0.02%)
NSE: 28 Mar 4:00 PM

Price Summary

Today's High

₹ 434.3

Today's Low

₹ 425.8

52 Week High

₹ 480.45

52 Week Low

₹ 272.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

10425.49 Cr.

Enterprise Value

11133.33 Cr.

No. of Shares

24.24 Cr.

P/E

22.47

P/B

3.46

Face Value

₹ 1

Div. Yield

0.35 %

Book Value (TTM)

₹  124.27

CASH

202.98 Cr.

DEBT

910.82 Cr.

Promoter Holding

41.96 %

EPS (TTM)

₹  19.14

Sales Growth

21.39%

ROE

19.17 %

ROCE

19.55%

Profit Growth

29.05 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year21.39%
3 Year19.39%
5 Year19.01%

Profit Growth

1 Year29.05%
3 Year3.95%
5 Year29.09%

ROE%

1 Year19.17%
3 Year21.22%
5 Year20.66%

ROCE %

1 Year19.55%
3 Year20.79%
5 Year19.32%

Debt/Equity

0.3391

Price to Cash Flow

15.71

Interest Cover Ratio

18.1676061436624

CFO/PAT (5 Yr. Avg.)

0.998178418953954

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 41.96 4.03
Sep 2023 41.96 4.03
Jun 2023 42.02 4.03
Mar 2023 42.02 4.03
Dec 2022 42.02 4.03
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 19.3918761212925% for the Past 3 years.
  • Company has been maintaining healthy ROE of 21.2236147096313% over the past 3 years.
  • Company has been maintaining healthy ROCE of 20.7919493516203% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 18.1676061436624.
  • The Company has been maintaining an effective average operating margins of 21.01905157355% in the last 5 years.
  • Company’s PEG ratio is 0.697170714360842.
  • The company has an efficient Cash Conversion Cycle of 60.7795393890619 days.

 Limitations

  • The company has shown a poor profit growth of 3.94915802466898% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 1032.39 1013.88 821 1009.42 984.49
Total Expenditure 793.77 796.58 664.23 800.99 737.6
Operating Profit 238.62 217.3 156.77 208.42 246.88
Other Income -0.93 2.56 0.44 1.25 0.67
Interest 11.76 14.12 14.79 17.65 19.78
Depreciation 38.32 37.77 35.27 36.01 36.16
Exceptional Items 0 0 0 0 0
Profit Before Tax 187.61 167.97 107.16 156.01 191.61
Tax 47.81 42.68 27.32 39.86 48.91
Profit After Tax 139.8 125.29 79.84 116.16 142.71
Adjusted EPS (Rs) 5.78 5.18 3.3 4.79 5.89

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 2098.43 2309.93 3134.98 3238.44 3931.2
Total Expenditure 1766.08 1815.79 2273.61 2594.4 3095.91
Operating Profit 332.35 494.14 861.37 644.04 835.29
Other Income 28.49 26.46 13.72 18.12 12.88
Interest 28.36 26.86 23.77 16.35 38.67
Depreciation 90.77 101.82 118.45 126.16 145.56
Exceptional Items 0 161.12 0 0 0
Profit Before Tax 241.71 553.03 732.87 519.65 663.94
Tax 79.87 108.96 180.09 133.13 165.16
Net Profit 161.84 444.07 552.78 386.52 498.79
Adjusted EPS (Rs.) 6.37 17.47 22.32 15.58 20.61

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 25.42 25.42 24.77 24.8 24.2
Total Reserves 1397.81 1786.16 2137.85 2505.86 2675.26
Borrowings 478.78 420.92 333.81 233.7 148.64
Other N/C liabilities 79.51 66.22 58.07 66.66 61.4
Current liabilities 842.84 847.45 1128.33 1541.6 1593.77
Total Liabilities 2824.37 3146.18 3682.83 4372.62 4503.27
Assets
Net Block 699.95 926.88 985 1170.83 1329.8
Capital WIP 308.74 100.86 146.58 194.15 63.46
Intangible WIP 24.28 28.92 17.43 16.38 0
Investments 506.46 445.39 591.53 596.53 676.53
Loans & Advances 76.02 169.24 64.42 64.08 115.52
Other N/C Assets 0 0 0 0 0
Current Assets 1208.91 1474.88 1877.87 2330.65 2317.97
Total Assets 2824.37 3146.18 3682.83 4372.62 4503.27
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 241.71 553.03 732.87 519.65 663.94
Adjustment 121.92 -53.91 153.72 137.11 178.19
Changes in Assets & Liabilities -49.97 115.3 -325.99 -233.77 -1.31
Tax Paid -86.8 -119.63 -185.94 -142.7 -177.14
Operating Cash Flow 226.85 494.79 374.66 280.29 663.68
Investing Cash Flow -242.91 -164.6 -232.74 -317.51 -96.71
Financing Cash Flow -17.33 -212.29 -296.21 151.43 -519.47
Net Cash Flow -33.39 117.9 -154.29 114.21 47.5

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 42.02 42.02 42.02 41.96 41.96
chigurupati uma devi 3.82 3.82 3.82 3.81 3.81
chigurupati priyanka 0.75 0.75 0.75 0.75 0.75
krishna prasad chigurupat... 34.83 34.83 34.83 34.78 34.78
nikhila reddy yedaguri 0.01 0.01 0.01 0.01 0.01
pragnya chigurupati 0.76 0.76 0.76 0.76 0.76
santhi sree ramanavarapu 0.35 0.35 0.35 0.35 0.35
suseela devi chigurupati 0.03 0.03 0.03 0.03 0.03
tyche investments private... 1.47 1.47 1.47 1.47 1.47
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 57.98 57.98 57.98 58.04 58.04
aditya birla sun life tru... 1.42 1.38 1.44 1.27 1.23
akash bhanshali - - - - 1.10
basava sankara rao kolli 1.21 - 1.21 - 1.21
fidelity funds - asian sm... 2.25 2.75 2.85 3.02 2.34
fidelity funds - india fo... 2.00 2.00 2.60 2.61 2.61
government pension fund g... 1.15 1.15 1.15 1.15 1.15
investor education and pr... 0.10 0.10 0.11 0.13 0.13
life insurance corporatio... - - 1.48 2.30 2.58
mahima stocks private lim... 1.11 1.11 1.11 1.13 1.13
quant mutual fund-quant e... - - - - 2.20
basava sankararao kolli - 1.21 - 1.21 -
fidelity asian values plc... - 1.09 1.09 1.09 -
ntasain discovery master ... - - - 1.24 -
ab sicav i - internationa... - - 1.02 - -
bnp paribas arbitrage 2.53 - 1.08 - -
bnp paribas arbitrage-odi... - 2.45 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Granules India informs about closure of trading window28 Mar 2024, 5:09PM Granules India informs about clarification23 Mar 2024, 3:35PM Granules India informs about appointment of CHRO11 Mar 2024, 5:00PM Granules India informs about appointment of additional director19 Feb 2024, 11:48AM Granules India - Quaterly Results23 Jan 2024, 12:20PM Granules India - Quaterly Results23 Jan 2024, 12:20PM Granules India - Quaterly Results23 Jan 2024, 12:20PM Granules India informs about disclosure 16 Dec 2023, 10:36AM Granules India informs about press release13 Dec 2023, 12:53PM Granules India gets USFDA’s approval for Pantoprazole Sodium Delayed-Release Tablets13 Dec 2023, 12:10PM Granules India’s arm gets USFDA’s approval for Sildenafil for Oral Suspension4 Dec 2023, 9:58AM Granules India informs about disclosure23 Nov 2023, 5:02PM Granules India informs about analyst meet 16 Nov 2023, 5:06PM Granules India - Quaterly Results9 Nov 2023, 1:11PM Granules India - Quaterly Results9 Nov 2023, 1:11PM Granules India - Quaterly Results9 Nov 2023, 1:11PM Granules India gets USFDA’s approval for Esomeprazole Magnesium Delayed-Release Capsules 19 Oct 2023, 12:38PM Granules India informs about press release19 Oct 2023, 12:32PM Granules India informs about allotment of equity shares under ESOS29 Sep 2023, 4:44PM Granules India receives Accreditation Certificate of Foreign Drug Manufacturer from PMDA 25 Aug 2023, 12:39PM Granules India gets nod from Brazilian Health Regulatory Agency25 Aug 2023, 9:22AM Granules India informs about audio recording of conference call 10 Aug 2023, 9:42AM Granules India - Quaterly Results9 Aug 2023, 3:40PM Granules India - Quaterly Results9 Aug 2023, 3:40PM Granules India - Quaterly Results9 Aug 2023, 3:40PM Granules India gets USFDA’s nod for Metoprolol Succinate ER Tablets8 Aug 2023, 2:08PM Granules India informs about press release4 Aug 2023, 9:57AM USFDA completes post-marketing Adverse Drug Experience inspection at Granules India’s arm4 Aug 2023, 9:19AM Granules India informs about analyst meet26 Jul 2023, 1:21PM Granules India informs about press release14 Jul 2023, 9:40AM Granules India gets USFDA’s approval for Store Brand OTC Equivalent of Advil Dual Action Tablets14 Jul 2023, 9:29AM USFDA issues EIR for Granules India’s Gagillapur facility in Hyderabad13 Jul 2023, 2:28PM USFDA completes PAI, GMP audit at Granules India’s Unit IV facility1 Jul 2023, 10:04AM Granules India informs about trading window closure28 Jun 2023, 1:55PM USFDA completes surveillance inspection at Granules India’s Jeedimetla facility 23 Jun 2023, 2:40PM Granules India informs about press release14 Jun 2023, 11:22AM Granules India gets USFDA’s approval for Levetiracetam Tablets14 Jun 2023, 10:58AM Granules India informs about press release13 Jun 2023, 12:31PM Granules India gets USFDA’s approval for Metoprolol Succinate ER Tablets13 Jun 2023, 11:59AM Granules India informs about press release19 May 2023, 9:39AM Granules India gets USFDA’s approval for Venlafaxine Hydrochloride Capsules19 May 2023, 9:06AM Granules India - Quaterly Results16 May 2023, 1:49PM Granules India - Quaterly Results16 May 2023, 1:49PM Granules India - Quaterly Results16 May 2023, 1:49PM Granules India informs about earnings conference call24 Apr 2023, 2:54PM Granules India informs about board meeting 24 Apr 2023, 12:42PM Granules India launches packaging facility in US29 Mar 2023, 11:46AM Granules India informs about press release29 Mar 2023, 10:00AM Granules India gets USFDA’s nod for Gabapentin Tablets 29 Mar 2023, 9:24AM USFDA concludes audit at Granules' arm facility with zero observations21 Mar 2023, 3:12PM

Granules India Stock Price Analysis and Quick Research Report. Is Granules India an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Granules India and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Granules India cash from the operating activity was Rs 663.678 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Granules India has a Debt to Equity ratio of 0.3391 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Granules India , the EPS growth was 32.2290451532593 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Granules India has OPM of 21.2476343101343 % which is a good sign for profitability.
     
  • ROE: Granules India have a average ROE of 19.1676132913795 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Granules India is Rs 430.15. One can use valuation calculators of ticker to know if Granules India share price is undervalued or overvalued.
Last Updated on:
Brief about Granules India

Granules India Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Granules India Ltd. is a renowned pharmaceutical company that manufactures and exports active pharmaceutical ingredients (APIs), intermediates, and finished dosages to several global markets. In this stock analysis page, we provide a comprehensive evaluation of Granules India Ltd.'s financial performance, growth potential, and other critical factors that affect its stock. Long-term stock investors looking for stock analysis can use this information to identify potential investment opportunities.

Granules India Ltd. Share Price:

Granules India Ltd.'s share price is a critical metric in evaluating its potential as a long-term stock investment opportunity. Our pre-built screening tools allow investors to track trends in the company's share price over time. Moreover, on our stock analysis page, we provide real-time information on the company's stock price, allowing investors to stay informed and make informed decisions based on current market conditions. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Granules India Ltd. Balance Sheet:

Granules India Ltd.'s balance sheet is essential in determining its financial stability and overall health as a long-term investment option. Analyzing the company's balance sheet enables investors to evaluate the strength of its financial health. By providing access to the company's balance sheet as a downloadable document, our website allows investors to evaluate its assets, liabilities, shareholders' equity, and other critical financial metrics. Our pre-built screening tools offer insights into the company's financial health, including its liquidity, debt levels, and other relevant ratios, making it easier to evaluate its growth potential.

Granules India Ltd. Annual Report:

Granules India Ltd.'s annual report offers valuable insights into the company's strategic initiatives, future goals, and financial performance over the fiscal year. Our website provides investors access to the annual report as a downloadable document, enabling them to evaluate the company's operations and potential for growth. Additionally, our pre-built screening tools offer insights into the company's financial health, allowing investors to analyze its long-term growth potential. Investors can gain deeper insights into the company's performance with our premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, enabling them to make informed investment decisions.

Granules India Ltd. Dividend:

Granules India Ltd.'s dividend payout policy plays a significant role in determining its growth potential over the long term. We provide investors with access to the company's dividend payout history, enabling them to analyze its performance. Our pre-built screening tools can help investors analyze Granules India Ltd.'s dividend payout trends, allowing them to make informed decisions regarding the company's growth potential.

Granules India Ltd. Quarterly Result:

Analyzing Granules India Ltd.'s quarterly results offers crucial insights into its financial performance, including revenue, profit & loss, and other critical financial metrics. Our website provides investors with access to these results as downloadable documents, enabling them to conduct an in-depth analysis of the company's performance. Our pre-built screening tools provide insights into the company's financial growth potential, helping investors make informed investment decisions.

Granules India Ltd. Stock Price:

Granules India Ltd.'s stock price performance is a crucial factor in evaluating its performance as a long-term investment option. Our stock analysis page provides real-time information on the company's stock price, enabling investors to track trends and identify potential investment opportunities. Additionally, our pre-built screening tools can help investors compare Granules India Ltd.'s stock price performance with that of its industry competitors, making it easier to evaluate its growth potential. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Granules India Ltd. Price Chart:

Visual representations of Granules India Ltd.'s share price trends over time can be valuable tools for long-term investors. Price charts enable investors to analyze the company's share price performance, identify trends, and determine potential investment opportunities. Our website provides access to Granules India Ltd.'s price chart, allowing investors to conduct an in-depth analysis of the company's performance. Our pre-built screening tools also enable investors to evaluate trends and compare the company's share price performance with that of industry competitors.

Granules India Ltd. News:

Staying up-to-date with the latest news and developments related to Granules India Ltd. is critical for long-term investors. Our website provides timely news articles about the company, offering updated insights into its financial performance and other critical information that may impact its growth potential. Our pre-built screening tool can also help investors track both local and global news, making it easier to analyze its market performance.

Granules India Ltd. Concall Transcripts:

Granules India Ltd.'s concall transcripts provide investors with valuable insights into the company's future guidance, including its strategic initiatives and financial performance. Our website provides access to these transcripts, enabling long-term investors to stay informed about the company's financial health. Our pre-built screening tools can help investors analyze the information provided in the transcripts, making it easier to make informed decisions about investing in the company's stock.

Granules India Ltd. Investor Presentations:

Analyzing Granules India Ltd.'s investor presentations is crucial in evaluating its potential as a long-term investment option. Our website provides access to these presentations as downloadable documents, enabling investors to analyze them in-depth. Our premium feature tools, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, can assist investors in analyzing the company's performance and making informed investment decisions.

Granules India Ltd. Promoters and Shareholders:

Analyzing Granules India Ltd.'s promoters and shareholders is essential in evaluating its potential as a long-term investment option. Our stock analysis page provides information about the company's promoters and other shareholders, enabling investors to make informed decisions about their investments. Our pre-built screening tools also enable investors to analyze the company's shareholding patterns, providing valuable insights into its growth potential.

Read More
X